Impact of Endoscopic and Histologic Activity on Disease Relapse in Ulcerative Colitis

被引:11
作者
Bessissow, Talat [1 ]
Kron, Chelsea Meadler [2 ]
Marcus, Victoria [2 ]
Lemieux, Carolyne [1 ]
Laneuville, Jennifer [1 ]
Afif, Waqqas [1 ]
Wild, Gary [1 ]
Lakatos, Peter L. [1 ,3 ]
Brassard, Paul [4 ]
Bitton, Alain [1 ]
机构
[1] McGill Univ, Dept Med, Div Gastroenterol & Hepatol, Hlth Ctr, Montreal, PQ, Canada
[2] McGill Univ, Dept Pathol, Hlth Ctr, Montreal, PQ, Canada
[3] Semmelweis Univ, Dept Med 1, Budapest, Hungary
[4] McGill Univ, Dept Med, Div Clin Epidmiol, Hlth Ctr, Montreal, PQ, Canada
关键词
INFLAMMATORY-BOWEL-DISEASE; CLINICAL RELAPSE; RISK; REMISSION; THERAPY;
D O I
10.14309/ajg.0000000000001912
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
INTRODUCTION: Endoscopic healing is currently considered the main target in the management of ulcerative colitis (UC). There are conflicting data about the role of histology as a stricter treatment objective. We aim at evaluating the additional benefit of histologic remission over endoscopic remission. METHODS: We performed a prospective observational study at the McGill University Health Center. We enrolled adult patients with UC in clinical remission for at least 3 months undergoing a colonoscopy. Endoscopic disease activity was based on the Mayo endoscopic score. Rectal biopsies were obtained, and the histologic activity was evaluated using the Geboes score (active disease defined as Geboes score >= 3.1) with the addition of assessing the presence of basal plasmacytosis. Patients were followed up for 12 months for disease relapse defined as a partial Mayo score of > 2. At the time of relapse or end of follow-up, all patients underwent repeat endoscopic evaluation. The primary end point was clinical relapse. RESULTS: Two hundred fifty-three patients were included. The presence of basal plasmacytosis was associated with relapse (adjusted odd ratio = 2.07, 95% confidence interval [CI] 1.06-4.18, P = 0.042). Time to clinical relapse was significantly higher for patients with Mayo endoscopic score > 0 with adjusted hazard ratio = 2.65, 95% CI 1.31-5.39, and P = 0.007. Time to clinical relapse was not significantly higher for Geboes score >= 3.1 with adjusted hazard ratio = 1.29, 95% CI 0.67-2.49, and P = 0.45. DISCUSSION: Active histologic disease did not affect time to clinical relapse in patients with UC who achieved endoscopic remission while the presence of basal plasmacytosis is associated with relapse.
引用
收藏
页码:1632 / 1638
页数:7
相关论文
共 21 条
  • [1] Hospitalisations and surgery in Crohn's disease
    Bernstein, Charles N.
    Loftus, Edward V., Jr.
    Ng, Siew C.
    Lakatos, Peter L.
    Moum, Bjorn
    [J]. GUT, 2012, 61 (04) : 622 - 629
  • [2] Prognostic Value of Serologic and Histologic Markers on Clinical Relapse in Ulcerative Colitis Patients With Mucosal Healing
    Bessissow, Talat
    Lemmens, Bart
    Ferrante, Marc
    Bisschops, Raf
    Van Steen, Kristel
    Geboes, Karel
    Van Assche, Gert
    Vermeire, Severine
    Rutgeerts, Paul
    De Hertogh, Gert
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (11) : 1684 - 1692
  • [3] Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis
    Bitton, A
    Peppercorn, MA
    Antonioli, DA
    Niles, JL
    Shah, S
    Bousvaros, A
    Ransil, B
    Wild, G
    Cohen, A
    Edwardes, MDD
    Stevens, AC
    [J]. GASTROENTEROLOGY, 2001, 120 (01) : 13 - 20
  • [4] Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission
    Cushing, Kelly C.
    Tan, William
    Alpers, David H.
    Deshpande, Vikram
    Ananthakrishnan, Ashwin N.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (03) : 347 - 355
  • [5] A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis
    D'Haens, Geert
    Sandborn, William J.
    Feagan, Brian G.
    Geboes, Karel
    Hanauer, Stephen B.
    Irvine, E. Jan
    Lemann, Marc
    Marteau, Philippe
    Rutgeerts, Paul
    Scholmerich, Jurgen
    Sutherland, Lloyd R.
    [J]. GASTROENTEROLOGY, 2007, 132 (02) : 763 - 786
  • [6] Consecutive Fecal Calprotectin Measurements to Predict Relapse in Patients with Ulcerative Colitis Receiving Infliximab Maintenance Therapy
    De Vos, Martine
    Louis, Edouard J.
    Jahnsen, Jorgen
    Vandervoort, Jo G. P.
    Noman, Maja
    Dewit, Olivier
    D'Haens, Geert R.
    Franchimont, Denis
    Baert, Filip J.
    Torp, Roald A.
    Henriksen, Magne
    Potvin, Philippe M. R.
    Van Hootegem, Philippe P.
    Hindryckx, Pieter M.
    Moreels, Tom G.
    Collard, Arnaud
    Karlsen, Lars Normann
    Kittang, Eirik
    Lambrecht, Guy
    Grimstad, Tore
    Koch, Jonas
    Lygren, Idar
    Coche, Jean-Claude R. J.
    Mana, Fazia
    Van Gossum, Andre
    Belaiche, Jacques
    Cool, Mike R.
    Fontaine, Fernand
    Maisin, Jean-Marc G.
    Muls, Vinciane
    Neuville, Bart
    Staessen, Dirk A. J.
    Van Assche, Gert A.
    de Lange, Thomas
    Solberg, Inger Camilla
    Vander Cruyssen, Bert J. K.
    Vermeire, Severine A. R. A.
    [J]. INFLAMMATORY BOWEL DISEASES, 2013, 19 (10) : 2111 - 2117
  • [7] Mucosal healing in inflammatory bowel disease: Results from a Norwegian population-based cohort
    Froslie, Kathrine Frey
    Jahnsen, Jorgen
    Moum, Bjorn A.
    Vatn, Morten H.
    [J]. GASTROENTEROLOGY, 2007, 133 (02) : 412 - 422
  • [8] Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing
    Jangi, Sushrut
    Yoon, Hyuk
    Dulai, Parambir S.
    Valasek, Mark
    Boland, Brigid S.
    Jairath, Vipul
    Feagan, Brian G.
    Sandborn, William J.
    Singh, Siddharth
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (06) : 1008 - 1016
  • [9] Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders (Publication with Expression of Concern)
    Magro, Fernando
    Gionchetti, Paolo
    Eliakim, Rami
    Ardizzone, Sandro
    Armuzzi, Alessandro
    Barreiro-de Acosta, Manuel
    Burisch, Johan
    Gecse, Krisztina B.
    Hart, Ailsa L.
    Hindryckx, Pieter
    Langner, Cord
    Limdi, Jimmy K.
    Pellino, Gianluca
    Zagorowicz, Edyta
    Raine, Tim
    Harbord, Marcus
    Rieder, Florian
    [J]. JOURNAL OF CROHNS & COLITIS, 2017, 11 (06) : 649 - 670
  • [10] Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission
    Narula, Neeraj
    Aruljothy, Achuthan
    Alshahrani, Abdul-Aziz
    Fadida, Ma'ayan
    Al-Saedi, Mona
    Marshall, John K.
    Rubin, David T.
    Christensen, Britt
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (11-12) : 1676 - 1682